Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 1, 2026, 12:19 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 99 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Blood draw at six months Clear all
Completed Phase 4 Interventional Results available

Mechanisms of Belatacept Effect on Alloimmunity and Antiviral Response After Kidney Transplantation (BMS IM 103-309)

NCT01953120
View directory record Official record
Conditions
Renal Transplant Rejection
Interventions
Belatacept
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 13, 2022 · Synced Oct 1, 2026, 12:19 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety of Switching From Rituximab to Ocrelizumab in MS Patients

NCT02980042
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Ocrelizumab, Rituximab
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 65 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 21, 2021 · Synced Oct 1, 2026, 12:19 AM EDT
Recruiting Not applicable Interventional

Gut Microbiome and Sex as Risk Factors for Kidney Stones After Bariatric Surgery

NCT04590690
View directory record Official record
Conditions
Bariatric Surgery Candidate
Interventions
Special diet
Other
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 130 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Oct 1, 2026, 12:19 AM EDT
Completed No phase listed Observational

Longitudinal Study of Multiple Symptoms in Advanced Lung Cancer

NCT00422500
View directory record Official record
Conditions
Lung Cancer
Interventions
Questionnaire, Telephone Interactive System, Blood Samples
Behavioral · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
4
States / cities
Miami, Florida • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 2, 2012 · Synced Oct 1, 2026, 12:19 AM EDT
Completed Phase 2 Interventional Results available

Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax

NCT01570036
View directory record Official record
Conditions
Breast Cancer
Interventions
Herceptin, NeuVax vaccine, GM-CSF
Drug
Lead sponsor
George E. Peoples
Industry
Eligibility
18 Years and older · Female only
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
29
States / cities
Beverly Hills, California • Santa Monica, California • Santa Rosa, California + 22 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2020 · Synced Oct 1, 2026, 12:19 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Assessing the Pharmacokinetics and Drug Interaction Liability of Kratom, an Opioid-like Natural Product

NCT04392011
View directory record Official record
Conditions
Interaction Drug Food
Interventions
Midazolam HCl, Dextromethorphan HBr, Kratom
Drug · Dietary Supplement
Lead sponsor
Washington State University
Other
Eligibility
18 Years to 55 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Spokane, Washington
Source: ClinicalTrials.gov public record
Updated Dec 20, 2023 · Synced Oct 1, 2026, 12:19 AM EDT
Completed Not applicable Interventional Results available

Metabolic Mapping and Cardiac Resynchronization

NCT03420833
View directory record Official record
Conditions
Heart Failure
Interventions
Cardiac resynchronization therapy pacemaker (CRT-P)
Device
Lead sponsor
Yong-Mei Cha
Other
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 23, 2025 · Synced Oct 1, 2026, 12:19 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003)

NCT06843447
View directory record Official record
Conditions
Ovarian Cancer Recurrent
Interventions
Raludotatug Deruxtecan, Carboplatin, Paclitaxel, Bevacizumab, Rescue Medication, Pembrolizumab, Gemcitabine, Pegylated liposomal doxorubicin, MK-2010
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older · Female only
Enrollment
605 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
10
States / cities
New Haven, Connecticut • Louisville, Kentucky • Shreveport, Louisiana + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 1, 2026, 12:19 AM EDT
Enrolling by invitation Phase 2 Interventional

Neoadjuvant Combination Therapy of Lenvatinib and TACE for Transplant-Eligible Large Hepatocellular Carcinoma Patients

NCT05171335
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Lenvatinib, Transcatheter Arterial Chemoembolization
Drug · Procedure
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 21, 2022 · Synced Oct 1, 2026, 12:19 AM EDT
Completed Not applicable Interventional

Fearon Algorithm in Warfarin Patient Self-Management

NCT03911661
View directory record Official record
Conditions
Atrial Fibrillation, Venous Thromboses, Heart Valve Diseases
Interventions
Fearon warfarin dosing algorithm, Usual care
Other
Lead sponsor
University of Utah
Other
Eligibility
22 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 17, 2023 · Synced Oct 1, 2026, 12:19 AM EDT
Recruiting Phase 2 Interventional

A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation

NCT06859424
View directory record Official record
Conditions
AML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL), Acute Leukemia (Category), MDS (Myelodysplastic Syndrome), CML (Chronic Myelogenous Leukemia), CLL (Chronic Lymphocytic Leukemia), Prolymphocyctic Leukemia, Chronic Myelomonocytic Leukemia (CMML), Myeloproliferative Neoplasm (MPN), Lymphoma, Myelofibrosis
Interventions
Conditioning Regimen A, Conditioning Regimen B, Conditioning Regimen C, Conditioning Regimen D, Conditioning Regimen E, Hematopoietic Cell Transplantation, PTCy (50 mg/kg D3, D4), PTCy (25 mg/kg D3, D4), Post-transplant Tacrolimus, Post-transplant Mycophenolate mofetil, Post-transplant Abatacept, Post-transplant Ruxolitinib, Supportive Care: Growth Factors, Supportive Care: Blood Products, Supportive Care: Infection Prophylaxis, Supportive Care: Intravenous immune globulin (IVIG), Supportive Care: Seizure prophylaxis, Supportive Care: Monitoring and management of CRS, Supportive Care: Prophylaxis against infections, Supportive Care: Prophylaxis against infections, Supportive Care: Lipid elevations, Study treatment compliance, Prohibited Concomitant Therapy, Permitted Concomitant Therapy
Drug · Procedure · Other
Lead sponsor
Center for International Blood and Marrow Transplant Research
Network
Eligibility
18 Years to 66 Years
Enrollment
358 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
13
States / cities
Birmingham, Alabama • Duarte, California • Palo Alto, California + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Oct 1, 2026, 12:19 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Understanding Patient Preference on Colorectal Cancer Screening Options

NCT05536713
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Guardant SHIELD blood-based colorectal cancer screening test
Device
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
45 Years to 75 Years
Enrollment
297 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 6, 2026 · Synced Oct 1, 2026, 12:19 AM EDT
Active, not recruiting Phase 4 Interventional

Treatment With Romosozumab Versus Denosumab to Improve Bone Mineral Density and Architecture in Subacute SCI

NCT05101018
View directory record Official record
Conditions
Osteoporosis, Spinal Cord Injuries
Interventions
Romosozumab, Denosumab
Drug
Lead sponsor
James J. Peters Veterans Affairs Medical Center
Federal
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
2
States / cities
West Orange, New Jersey • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Sep 17, 2025 · Synced Oct 1, 2026, 12:19 AM EDT
Completed Phase 2 Interventional Results available

A Trial of the Pharmacokinetics, Safety, and Tolerability of Subcutaneous Gamunex® in Primary Immunodeficiency

NCT00389324
View directory record Official record
Conditions
Immunologic Deficiency Syndrome
Interventions
Immune Globulin Intravenous (Human)
Biological
Lead sponsor
Grifols Therapeutics LLC
Industry
Eligibility
13 Years to 75 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
6
States / cities
Irvine, California • Los Angeles, California • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2015 · Synced Oct 1, 2026, 12:19 AM EDT
Recruiting Not applicable Interventional

Virtual Incentive Treatment for Alcohol

NCT06265506
View directory record Official record
Conditions
Alcohol Use Disorder, Alcohol Drinking, Alcohol Abuse, Alcohol Dependence
Interventions
Contingency Management, Computer Based Training for Cognitive Behavioral Therapy for AUD (CBT4CBT)
Behavioral
Lead sponsor
Washington State University
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Spokane, Washington
Source: ClinicalTrials.gov public record
Updated May 30, 2025 · Synced Oct 1, 2026, 12:19 AM EDT
Not listed No phase listed Observational

Breast Cancer Liquid Biopsy Trial

NCT04962529
View directory record Official record
Conditions
Breast Cancer, Cancer
Interventions
Blood Draw
Procedure
Lead sponsor
Anthony Magliocco
Industry
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
7
States / cities
Hollywood, Florida • Ocala, Florida • Orlando, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2022 · Synced Oct 1, 2026, 12:19 AM EDT
Terminated No phase listed Observational

An In-vitro Standardization of B Cell Elispot Assays

NCT01334281
View directory record Official record
Conditions
Transplant Sensitization, Panel Reactive Antibody, Sensitization to HLA Antigens
Interventions
Blood Draw
Procedure
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 22, 2013 · Synced Oct 1, 2026, 12:19 AM EDT
Active, not recruiting Phase 2 Interventional

Romosozumab/Denosumab Study for Premenopausal IOP

NCT04800367
View directory record Official record
Conditions
Premenopausal Idiopathic Osteoporosis
Interventions
Romosozumab Prefilled Syringe [Evenity], Denosumab 60 MG/ML Prefilled Syringe [Prolia]
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 1, 2026, 12:19 AM EDT
Recruiting Phase 2 Interventional

Limited-duration Teclistamab

NCT05932680
View directory record Official record
Conditions
Myeloma Multiple
Interventions
Off Drug Surveillance
Other
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
5
States / cities
Little Rock, Arkansas • Iowa City, Iowa • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2025 · Synced Oct 1, 2026, 12:19 AM EDT
Completed Not applicable Interventional

A Pilot Stress Management Intervention Study for High Risk Children With Asthma

NCT02091648
View directory record Official record
Conditions
Asthma
Interventions
I Can Cope Intervention, Standard Education Intervention
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
8 Years to 14 Years
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 5, 2016 · Synced Oct 1, 2026, 12:19 AM EDT
Completed Not applicable Interventional

MINDSPACE Strategy for Risk Optimization

NCT02721446
View directory record Official record
Conditions
Stroke
Interventions
Standard, Incentive, Salience, Incentive + Salience
Behavioral
Lead sponsor
Indiana Institute for Medical Research
Other
Eligibility
18 Years and older
Enrollment
641 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 17, 2018 · Synced Oct 1, 2026, 12:19 AM EDT
Active, not recruiting Phase 2 Interventional

Denosumab Treatment for Fibrous Dysplasia

NCT03571191
View directory record Official record
Conditions
Bone Diseases, Pain
Interventions
Denosumab
Drug
Lead sponsor
National Institute of Dental and Craniofacial Research (NIDCR)
NIH
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2030
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 18, 2022 · Synced Oct 1, 2026, 12:19 AM EDT
Completed Not applicable Interventional

Biopsychosocial Effect of Service Dog Training on Post-traumatic Stress (PTS) and Post Concussive Symptoms

NCT03907254
View directory record Official record
Conditions
Post-traumatic Stress Disorder, Posttraumatic Stress Disorder, Traumatic Brain Injury
Interventions
Service Dog Training Program
Other
Lead sponsor
Henry M. Jackson Foundation for the Advancement of Military Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 3, 2025 · Synced Oct 1, 2026, 12:19 AM EDT
Completed Phase 3 Interventional Results available

Rituximab Vasculitis Maintenance Study

NCT01697267
View directory record Official record
Conditions
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Microscopic Polyangiitis, Wegener Granulomatosis
Interventions
Rituximab, Azathioprine
Biological · Drug
Lead sponsor
Cambridge University Hospitals NHS Foundation Trust
Other
Eligibility
15 Years and older
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
9
States / cities
Los Angeles, California • Ann Arbor, Michigan • Rochester, Minnesota + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2022 · Synced Oct 1, 2026, 12:19 AM EDT